- BOSTON, June 19 (Reuters) - Alexander Denner, managing director of the Icahn investment vehicle Icahn Partners, said on Thursday that Biogen Idec Inc appears to have won a proxy battle with billionaire investor Carl Icahn.
- Speaking at the company's annual meeting, Denner congratulated Biogen on winning the vote for its slate of nominees to the board, beating an opposing slate nominated by Icahn.
- Biogen has yet to formally announce results of the vote. The meeting is still ongoing.
- Biogen's board had nominated Cecil Pickett, its president of research and development; Lynn Schenk, an attorney; and Phillip Sharp, a Nobel prize-winner who helped found Biogen 30 years ago.
- It also nominated Stelios Papadopoulos, a retired vice chairman of Cowen & Co, to replace Thomas Keller, who is reaching retirement age and will not stand again.
- Icahn had nominated Denner, Richard Mulligan, professor of genetics at Harvard Medical School; and Dr. Anne Young, head of the neurology service at Massachusetts General Hospital.
|
